NO20081919L - Farmasoytiske preparater for behandling av forstyrrelser i det indre oret - Google Patents
Farmasoytiske preparater for behandling av forstyrrelser i det indre oretInfo
- Publication number
- NO20081919L NO20081919L NO20081919A NO20081919A NO20081919L NO 20081919 L NO20081919 L NO 20081919L NO 20081919 A NO20081919 A NO 20081919A NO 20081919 A NO20081919 A NO 20081919A NO 20081919 L NO20081919 L NO 20081919L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- inner ear
- disorders
- pharmaceutical preparations
- preparations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Acoustics & Sound (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer preparater som inneholder (i) et farmasøytisk aktivt middel utvalgt fra gruppen som består av et arylsykloalkylamin eller et derivat, en analog eller et farmasøytisk aktivt salt derav, og (ii) en bioforenlig polymer eller en kombinasjon av bioforenlige polymerer. Disse preparatene eller medikamenter som inneholder disse preparatene kan anvendes for forebyggelse og/eller behandling av sykdommer i det indre øret, f. eks tinnitus.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2005/010478 WO2007038949A1 (en) | 2005-09-28 | 2005-09-28 | Pharmaceutical compositions for the treatment of inner ear disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20081919L true NO20081919L (no) | 2008-04-22 |
NO339356B1 NO339356B1 (no) | 2016-12-05 |
Family
ID=37019770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20081919A NO339356B1 (no) | 2005-09-28 | 2008-04-22 | Farmasøytiske preparater for behandling av forstyrrelser i innerøret |
Country Status (25)
Country | Link |
---|---|
US (5) | US20090246255A1 (no) |
EP (2) | EP2792347A1 (no) |
JP (1) | JP2009509982A (no) |
KR (1) | KR101271263B1 (no) |
CN (1) | CN101309667A (no) |
AU (1) | AU2005337107B2 (no) |
BR (1) | BRPI0520588B8 (no) |
CA (1) | CA2620374C (no) |
CU (1) | CU20080044A7 (no) |
CY (1) | CY1115891T1 (no) |
DK (1) | DK1928405T3 (no) |
EA (1) | EA017264B1 (no) |
ES (1) | ES2524994T3 (no) |
HR (1) | HRP20140920T1 (no) |
IL (1) | IL189622A (no) |
ME (1) | ME01956B (no) |
NO (1) | NO339356B1 (no) |
NZ (1) | NZ566062A (no) |
PL (1) | PL1928405T3 (no) |
PT (1) | PT1928405E (no) |
RS (1) | RS53591B1 (no) |
SI (1) | SI1928405T1 (no) |
TN (1) | TNSN08079A1 (no) |
WO (1) | WO2007038949A1 (no) |
ZA (1) | ZA200802762B (no) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531726A (ja) * | 2005-03-04 | 2008-08-14 | ニューロシステック コーポレイション | 改良されたガシクリジン製剤 |
SI1928405T1 (sl) | 2005-09-28 | 2014-12-31 | Auris Medical Ag | Farmacevtski sestavki za zdravljenje motenj notranjega ušesa |
US20070110788A1 (en) * | 2005-11-14 | 2007-05-17 | Hissong James B | Injectable formulation capable of forming a drug-releasing device |
US20090088844A1 (en) * | 2007-07-03 | 2009-04-02 | Keegan Mark E | Drug-eluting stapes prosthesis |
CN104491864A (zh) | 2008-04-21 | 2015-04-08 | 奥德纳米有限公司 | 用于治疗耳部疾病和病况的耳用调配物及方法 |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
CN102026623B (zh) * | 2008-05-14 | 2013-08-14 | 奥德纳米有限公司 | 用于治疗耳部病症的控制释放皮质类固醇组合物和方法 |
US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
US8349353B2 (en) | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
GB2461962B (en) * | 2008-07-25 | 2011-02-16 | Otonomy Inc | Slow release NMDA receptor antagonist for otic disorders |
WO2010008995A2 (en) * | 2008-07-14 | 2010-01-21 | Otonomy, Inc. | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
EP2306975A4 (en) * | 2008-07-21 | 2012-10-31 | Otonomy Inc | CONTROLLED RELEASE COMPOSITIONS MODULATING THE OTIC STRUCTURE AND MODULATING THE NATURAL IMMUNE SYSTEM AND METHODS OF TREATING OTIC DISORDERS |
US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
MX2011000862A (es) * | 2008-07-21 | 2011-03-15 | Otonomy Inc | Composiciones antimicrobianas de liberacion controlada y metodos para el tratamiento de trastornos oticos. |
US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
EP2344151A4 (en) | 2008-10-22 | 2012-04-18 | House Ear Inst | THERAPEUTIC AND / OR PROPHYLACTIC TREATMENT OF INTERNAL EAR PATHOLOGIES BY MODULATION OF THE METABOTROPIC GLUTAMATE RECEPTOR |
AU2009330458B2 (en) * | 2008-12-22 | 2013-08-22 | Otonomy, Inc. | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
EP2201982A1 (en) | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
EP2409683A1 (en) | 2010-07-06 | 2012-01-25 | KRKA, D.D., Novo Mesto | Stable aqueous formulations comprising poorly water soluble active ingredients |
WO2013003669A2 (en) * | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
US10130514B2 (en) * | 2011-09-26 | 2018-11-20 | Incube Labs, Llc | System and method for delivery of a therapeutic agent to the inner ear |
US20150044200A1 (en) | 2011-12-12 | 2015-02-12 | Otolanum Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
AU2013328280B2 (en) | 2012-10-08 | 2017-12-21 | Auckland Uniservices Limited | Ketamine derivatives |
US20140348787A1 (en) * | 2013-05-22 | 2014-11-27 | Professional Compounding Centers Of America | Methods and Compositions for Treating Ear Infections |
MX2016002408A (es) | 2013-08-27 | 2016-10-28 | Otonomy Inc | Metodos para el tratamiento de trastornos oticos pediatricos. |
HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
WO2015051259A1 (en) * | 2013-10-04 | 2015-04-09 | Impax Laboratories, Inc. | Pharmaceutical compositions and methods of use |
WO2015191950A1 (en) * | 2014-06-12 | 2015-12-17 | Orbis Biosciences, Inc. | Extended-release drug delivery compositions |
WO2017139382A1 (en) * | 2016-02-08 | 2017-08-17 | The Texas A&M University System | Combination of adjuvant drugs esketamine and brimonidine for medical treatments |
EP3512513A4 (en) | 2016-09-16 | 2020-04-15 | Otonomy, Inc. | GEL FORMULA FOR THE EAR FOR TREATING OTITIS EXTERNA |
KR20230110828A (ko) | 2018-01-10 | 2023-07-25 | 엑스더블유파마 리미티드 | 케타민의 전구약물, 및 이의 조성물 및 용도 |
JP7492917B2 (ja) | 2018-02-09 | 2024-05-30 | デシベル セラピューティクス インコーポレイテッド | 抗白金化学保護剤を含む高張医薬組成物 |
WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
WO2019186357A1 (en) * | 2018-03-26 | 2019-10-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | DRUG TREATMENT METHODS |
US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
US20200214976A1 (en) * | 2019-01-09 | 2020-07-09 | Spiral Therapeutics, Inc. | Self-gelling solutions for administration of therapeutics to the inner ear |
US20220054420A1 (en) * | 2020-08-18 | 2022-02-24 | Oakwood Laboratories, Llc | Microsphere formulations comprising ketamine and methods for making and using the same |
WO2022140636A1 (en) * | 2020-12-22 | 2022-06-30 | Otonomy, Inc. | Gacyclidine otic formulations and uses thereof |
US11753378B2 (en) | 2021-04-19 | 2023-09-12 | Zevra Therapeutics, Inc. | Ketamine compounds and processes for making and using them |
US11690811B2 (en) | 2021-08-13 | 2023-07-04 | XWPharma Ltd. | Pharmaceutical compositions and oral dosage forms of ketamine derivatives |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3254124A (en) * | 1962-06-29 | 1966-05-31 | Parke Davis & Co | Aminoketones and methods for their production |
CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
US5421818A (en) | 1993-10-18 | 1995-06-06 | Inner Ear Medical Delivery Systems, Inc. | Multi-functional inner ear treatment and diagnostic system |
EP0772225B1 (en) * | 1994-07-15 | 2003-03-19 | Hitachi, Ltd. | Electronic energy filter |
EP0788359B1 (en) * | 1994-09-22 | 2006-07-12 | Richard Alan Smith | Combination of dextromethorphan with quinidine or quinine sulfate for treating a variety of intractable disorders |
US5945409A (en) * | 1995-03-10 | 1999-08-31 | Wilson T. Crandall | Topical moisturizing composition and method |
US5654337A (en) * | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
DE19528388A1 (de) | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
TW450807B (en) * | 1995-09-15 | 2001-08-21 | Pfizer | Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents |
AU2676397A (en) | 1996-04-18 | 1997-11-07 | University Technology Corporation | Methods for treating middle and inner ear disorders |
AU4424697A (en) * | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity |
US6045528A (en) | 1997-06-13 | 2000-04-04 | Intraear, Inc. | Inner ear fluid transfer and diagnostic system |
US6309410B1 (en) | 1998-08-26 | 2001-10-30 | Advanced Bionics Corporation | Cochlear electrode with drug delivery channel and method of making same |
DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
US6120484A (en) * | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
CA2373994A1 (en) * | 1999-05-24 | 2000-11-30 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6017961A (en) * | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
DE19936719A1 (de) * | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
US6265379B1 (en) * | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
JP2001187737A (ja) * | 1999-10-18 | 2001-07-10 | Toyama Chem Co Ltd | 聴力改善剤 |
AU2001257295A1 (en) | 2000-05-01 | 2001-11-12 | Georgetown University | In vivo assay for identifying nucleic acid sequences involved in alveolar loss, development and nucleic acid sequences identified thereby |
DE10025238A1 (de) * | 2000-05-22 | 2001-11-29 | Gruenenthal Gmbh | Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel |
BRPI0002693B8 (pt) | 2000-06-19 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis |
DE10044649A1 (de) * | 2000-09-08 | 2002-07-04 | Gruenenthal Gmbh | Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine |
US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
DE10124953A1 (de) | 2001-05-21 | 2002-12-12 | Marlies Knipper | Substanz für die therapeutische Behandlung von Tinnitus |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
US20030143195A1 (en) * | 2002-01-30 | 2003-07-31 | Pinsker Judy Senior | Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
US6638081B2 (en) * | 2002-03-22 | 2003-10-28 | Hon Hai Precision Ind. Co., Ltd. | Electrical connector |
US20040037311A1 (en) | 2002-08-07 | 2004-02-26 | Phonex Broadband Corporation | Digital narrow band power line communication system |
EP1545551A4 (en) | 2002-09-06 | 2008-10-22 | Durect Corp | DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR |
US6969383B2 (en) * | 2002-09-27 | 2005-11-29 | Medtronic, Inc. | Method for treating severe tinnitus |
US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
EP1560807B1 (de) | 2002-11-12 | 2010-02-10 | Grünenthal GmbH | 4-hydroxymethyl-1-aryl-cyclohexylamin-derivative |
US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
EP1438942A1 (en) | 2003-01-17 | 2004-07-21 | Schering Oy | An otorhinological drug delivery device |
WO2004101072A1 (en) | 2003-05-16 | 2004-11-25 | Universite Laval | Cns chloride modulation and uses thereof |
US8030362B2 (en) | 2003-12-12 | 2011-10-04 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
US8268866B2 (en) * | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
SI1928405T1 (sl) | 2005-09-28 | 2014-12-31 | Auris Medical Ag | Farmacevtski sestavki za zdravljenje motenj notranjega ušesa |
-
2005
- 2005-09-28 SI SI200531901T patent/SI1928405T1/sl unknown
- 2005-09-28 JP JP2008532601A patent/JP2009509982A/ja active Pending
- 2005-09-28 AU AU2005337107A patent/AU2005337107B2/en not_active Ceased
- 2005-09-28 PL PL05797324T patent/PL1928405T3/pl unknown
- 2005-09-28 CN CNA2005800517036A patent/CN101309667A/zh active Pending
- 2005-09-28 CU CU20080044A patent/CU20080044A7/es unknown
- 2005-09-28 PT PT05797324T patent/PT1928405E/pt unknown
- 2005-09-28 KR KR1020087007345A patent/KR101271263B1/ko active IP Right Grant
- 2005-09-28 EP EP14001796.3A patent/EP2792347A1/en not_active Withdrawn
- 2005-09-28 EP EP05797324.0A patent/EP1928405B1/en active Active
- 2005-09-28 EA EA200800798A patent/EA017264B1/ru not_active IP Right Cessation
- 2005-09-28 ME MEP-2014-138A patent/ME01956B/me unknown
- 2005-09-28 ES ES05797324.0T patent/ES2524994T3/es active Active
- 2005-09-28 RS RSP20140607 patent/RS53591B1/en unknown
- 2005-09-28 BR BRPI0520588A patent/BRPI0520588B8/pt active IP Right Grant
- 2005-09-28 CA CA 2620374 patent/CA2620374C/en active Active
- 2005-09-28 NZ NZ566062A patent/NZ566062A/en not_active IP Right Cessation
- 2005-09-28 DK DK05797324T patent/DK1928405T3/da active
- 2005-09-28 WO PCT/EP2005/010478 patent/WO2007038949A1/en active Application Filing
- 2005-09-28 US US11/992,632 patent/US20090246255A1/en not_active Abandoned
-
2008
- 2008-02-20 IL IL189622A patent/IL189622A/en active IP Right Grant
- 2008-02-21 TN TNP2008000079A patent/TNSN08079A1/en unknown
- 2008-03-28 ZA ZA2008/02762A patent/ZA200802762B/en unknown
- 2008-04-22 NO NO20081919A patent/NO339356B1/no not_active IP Right Cessation
-
2014
- 2014-06-27 US US14/317,319 patent/US9066865B2/en active Active
- 2014-09-25 HR HRP20140920TT patent/HRP20140920T1/hr unknown
- 2014-12-02 CY CY20141101004T patent/CY1115891T1/el unknown
-
2015
- 2015-03-27 US US14/671,524 patent/US20150196569A1/en not_active Abandoned
- 2015-03-27 US US14/671,527 patent/US20150265532A1/en not_active Abandoned
- 2015-05-22 US US14/720,212 patent/US20150250719A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20081919L (no) | Farmasoytiske preparater for behandling av forstyrrelser i det indre oret | |
NO20075660L (no) | Blanding for behandling av inflammatoriske sykdommer | |
AU2018338608A1 (en) | Methods, compositions, and implantable elements comprising active cells | |
WO2008087488A3 (en) | Expandable medical device for the treatment and prevention of cardiovascular diseases | |
NO20043309L (no) | Legemiddelleveringssystemer for hindring og behandling av vaskulaere sykdommer som innbefatter rapamycin og derivater derav | |
CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
NO20081844L (no) | Terapeutiske forbindelser | |
NO20084328L (no) | Nye forbindelser | |
WO2007087548A3 (en) | Chemical compounds | |
AU2003245282A1 (en) | Stent coatings with sustained drug release rate | |
NO20074703L (no) | Antibakterielle piperidinderivater | |
NO340679B1 (no) | Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer | |
NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
NO20084257L (no) | Diketopiperazin og piperidin derivater som antivirale midler | |
WO2007149406A3 (en) | Modified coagulation factor ix polypeptides and use thereof for treatment | |
MY142589A (en) | Benzimidazole derivatives : preparation and pharmaceutical applications | |
FR2949062B1 (fr) | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments | |
NO20090346L (no) | Pyrazolderivater som inhibitorer av cytokrom P450 | |
NO20084935L (no) | Nikotinbaerende vaksineformulering | |
DK1906916T3 (da) | Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser | |
WO2006096444A3 (en) | Chemical compounds | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme | |
WO2022175746A8 (en) | Tyk2 inhibitors and uses thereof | |
NO20080133L (no) | Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |